David K. Lee, CEO of Servier Pharmaceuticals, shared a post on LinkedIn:
“Following the close of the Day One Biopharmaceuticals acquisition, I made the trip to Brisbane to visit with our new team.
Day One gets its name from “The Day One Talk,” the conversation that divides a family’s life into before and after a pediatric cancer diagnosis.
Building a company inspired by that moment says something about the people it attracts. What struck me when spending time with our new colleagues was their deep concern for patients.
They focus on pediatric cancer not because of market potential, but because the unmet need is urgent and the science is within reach. That is the kind of choice that Servier Pharmaceuticals, as an independent organization governed by a nonprofit, was built to support.
We’re proud to have the Day One team join us as we co-build a future focused on a shared commitment to the patients others with high unmet need.
I look forward to honoring that commitment together.”
Other articles featuring David K. Lee on OncoDaily.